Interferon regulatory factors in human lupus pathogenesis

Translational Research

Volumn 157, Issue 6, 2011, Pages 326-331

  Salloum, Rafah ^a   Niewold, Timothy B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DNA; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; NUCLEIC ACID; TOLL LIKE RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE; GENOTYPE; HUMAN; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 79956141306     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2011.01.006     Document Type: Review

References (54)

1. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8. (Pubitemid 9226519)
2. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32. (Pubitemid 39576902)
3. Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:948364.
4. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481-90. (Pubitemid 37498244)
5. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-5. (Pubitemid 36297546)
6. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207-10. (Pubitemid 20075945)
7. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24:178-81. (Pubitemid 40552976)
8. Niewold TB. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol 2008;14:131-2.
9. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502. (Pubitemid 47365615)
10. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-related patterns of serum interferonalpha activity in lupus families. Arthritis Rheum 2008;58:2113-9. (Pubitemid 351988103)
11. Kariuki SN, Franek BS, Kumar AA, et al. Trait-stratified genomewide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R151.
12. Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 2008;58:2818-23.
13. Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun 2009;10:487-94.
14. Kariuki SN, Niewold TB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res 2010;155:109-17.
15. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009;182:34-8.
16. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011.
17. Kariuki SN, Franek BS, Mikolaitis RA, et al. Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients. J Biomed Biotechnol 2010;2010:826434.
18. Lodolce JP, Kolodziej LE, Rhee L, et al. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol 2010;184:7001-9.
19. Salloum R, Franek BS, Kariuki SN, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum 2010;62:553-61.
20. Pothlichet J, Niewold TB, Vitour D, et al. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med 2011, in press.
21. Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38:550-5.
22. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genomewide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-10. (Pubitemid 351171405)
23. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008;58:2481-7.
24. Rullo OJ, Woo JM, Wu H, et al. Association of IRF5 polymorphisms with activation of the interferon alpha pathway. Ann Rheum Dis 2010;69:611-7.
25. Feng D, Stone RC, Eloranta ML, et al. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:562-73.
26. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res 2010;59:791-808.
27. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861-72. (Pubitemid 38725099)
28. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006;54:1917-27. (Pubitemid 43877941)
29. Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 2008;58:2818-23.
30. Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007;89:744-53. (Pubitemid 47001634)
31. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008;26:535-84. (Pubitemid 351600385)
32. Battistini A. Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J Interferon Cytokine Res 2009;29:765-80.
33. Wang H, Morse HC 3rd. IRF8 regulates myeloid and B lymphoid lineage diversification. Immunol Res 2009;43:109-17.
34. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31. (Pubitemid 351969894)
35. Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007;104:6758-63. (Pubitemid 47175574)
36. Gateva V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009;41:1228-33.
37. Tsujimura H, Tamura T, Kong HJ, et al. Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/ IFN consensus sequence binding protein in dendritic cells. J Immunol 2004;172:6820-7. (Pubitemid 38669120)
38. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003;63:6424-31. (Pubitemid 37255192)
39. Barnes BJ,Moore PA, PithaPM.Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001;276:23382-90.
40. Reddy MV, Velazquez-Cruz R, Baca V, et al. Genetic association of IRF5 with SLE in Mexicans: higher frequency of the risk haplotype and its homozygozity than Europeans. Hum Genet 2007;121:721-7. (Pubitemid 46916971)
41. Shin HD, Kim I, Choi CB, Lee SO, Lee HW, Bae SC. Different genetic effects of interferon regulatory factor 5 (IRF5) polymorphisms on systemic lupus erythematosus in a Korean population. J Rheumatol 2008;35:2148-51.
42. Kawasaki A, Kyogoku C, Ohashi J, et al. Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms. Arthritis Rheum 2008;58:826-34. (Pubitemid 351364880)
43. Kelly JA, Kelley JM, Kaufman KM, et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun 2008;9:187-94. (Pubitemid 351584185)
44. Siu HO, Yang W, Lau CS, et al. Association of a haplotype of IRF5 gene with systemic lupus erythematosus in Chinese. J Rheumatol 2008;35:360-2. (Pubitemid 351281165)
45. Sigurdsson S, Goring HH, Kristjansdottir G, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008;17:872-81. (Pubitemid 351368993)
46. Wen F, Ellingson SM, Kyogoku C, Peterson EJ, Gaffney PM. Exon 6 variants carried on systemic lupus erythematosus (SLE) risk haplotypes modulate IRF5 function. Autoimmunity 2010.
47. Richez C, Yasuda K, Bonegio RG, et al. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol 2010;184:796-806.
48. Zhang L, Pagano JS. Structure and function of IRF-7. J Interferon Cytokine Res 2002;22:95-101. (Pubitemid 34161287)
49. De Jager PL, Jia X,Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;41:776-82.
50. Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 2006;110:35-56. (Pubitemid 43248725)
51. Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol 2011;40:42-9.
52. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006;39:63-70. (Pubitemid 43878521)
53. Lenert P. Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus. Clin Exp Immunol 2010;161:208-22.
54. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferonalpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.